Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies addresses areas of unmet medical need, with a focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel modulator for the treatment of epilepsy; XEN496, a Kv7 potassium channel modulator for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN007, which is a CNS-acting Cav2.1 and T-type calcium channel modulator that is being studied in treatment-resistant childhood absence epilepsy, or CAE, and potentially other neurological disorders. The XENE stock yearly return is shown above.
The yearly return on the XENE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the XENE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|